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DEVELOPMENT AND CHARACTERIZATION OF MONOCLONAL
ANTIBODIES DIRECTED AGAINST YABA-LIKE
DISEASE VIRUS
Scott Haller, M.S.
Western Michigan University, 2001
The hybridoma technique has been used for the production of monoclonal
antibodies (mAb) directed against yaba-like disease virus (YLDV). Spleen cells,
obtained from female BALB/c mice immunized with YLDV, were fused with
P3x63.Ag8.653 myeloma cells and hybrids were selected. Hybridoma clones were
screened for production of anti-YLDV antibodies by Indirect Immunofluorescence
(IF) microscopy. Positive hybridoma clones were recloned via limiting dilution and
characterized. A single clone (H12) has been selected that specifically reacted with
YLDV infected cells and not uninfected cells. Immunodiffusion technique determined
H12 monoclonal antibody as an IgG1 isoptype immunoglobulin.

H12 antibodies

recognized a late YLDV protein, and cross-reacted with tanapox virus (TPV) infected
cells providing additional evidence to classify YLDV and TPV as different strains of
the same virus. The approximate molecular weight of the antigen has yet to be
confirmed. The H12 mAb should prove invaluable in the elucidation of the virus-host
interactions with YLDV and TPV potential diagnosis of these infections in humans
and monkeys.

TABLE OF CONTENTS

ACKNOWLEDGMENTS..................................................................

ll

LIST OF TABLES...........................................................................

VI

LIST OF FIGURES.........................................................................

vu

INTRODUCTION....................................................................

1

Poxviruses.....................................................................

1

Tanapox Virus and Yaba-Like Disease Virus.............................

3

Classification..........................................................

3

Epidemiology ofTPV and YLDV.................................

4

Morphology ofTPV and YLDV Virions.........................

5

Biological Similarities ofTPV and YLDV.......................

6

TPV and YLDV Genomes..........................................

7

Monoclonal Antibodies......................................................

7

History ofAntibody Discovery....................................

7

BriefHistory ofMonoclonal Antibody Technology............

8

Myeloma Cells: Non-Secreting Immortal Fusion Partner......

9

Techniques for Cell Fusion and Hybridoma Selection..........

10

Applications ofMonoclonal Antibodies..........................

12

Conclusions...........................................................

16

Ill

Table ofContents- continued
MATERIALS AND METHODS....................................................

17

Virus, Cells and Reagents for Virus Cultivation............................ 17
Virus Concentration............................................................

17

Immunization..................................................................

19

Fusion...........................................................................

19

Myeloma Cells and Reagents.......................................

19

Myeloma Cell Quantification.......................................

20

"Feeder Cells".........................................................

21

Fusion Protocol........................................................

22

Hybridoma Screening Assay.................................................. 24
Collection ofHybridoma Supernatant..............................

24

Development ofCoverslips.........................................

25

Indirect Immunofluorescence (IF) Assay....'....................

25

Maintenance ofPositive Clones............................................

27

Cloning by Limiting Dilution......................................

27

Cryopreservation ofHybridoma Cells............................

28

Test ofCryopreserved Hybridoma Viability.....................

28

Hybridoma Characterization.................................................

29

Hybridoma Supernatant Concentration...........................

29

Indirect Immunofluorescence (IF) Assay and Digital Imaging.

30

Hybridoma Isotype Determination- Immunodiffilsion Assay..

30

IV

Table of Contents- continued
Immunoprecipitation of Viral Antigen by Sodium Dodecyl
Sulphate Polyacrylamide Gel Electrophoresis................................... 31
Preparation on Radio labeled Viral Antigen............................. 31
SDS-PAGE Resolution of Viral Antigen................................ 33
Hybridoma Cross Reactivity Assay..............................................

35

Determination of Viral Antigen as Either an Early or
Late Protein........................................................................... 35
RESULTS................................................................................... 37
Development of Monoclonal Antibodies Directed Against
Yaba-Like Disease Virus.......................................................... 37
Hybridoma Clone H12 Produces IgGl Isotype Antibody..................... 39
Indirect Immunofluorescence Microscopy with H12 Hybridoma
Supernatant........................................................................... 40
H12 Antibody is Directed Against a Late YLDV Polypeptide................ 44
H12 Antibody Demonstrates Cross Reactivity with TPV through
Indirect Immunofluorescence Microscopy....................................... 47
Immunoprecipitation of Viral Antigen with H12 Supernatant
Demonstrates Two Polypeptide Chains Precipitated............................ 49
DISCUSSION................................................................................. 51
APPENDICES
A.

IACUC Approval Letter .................................................... 54

B.

Radiation Safety............................................................. 56

BIBLIOGRAPHY............................................................................ 58

V

LIST OF TABLES
1.

Summary of Number of Wells Screened per Fusion with
Immunofluorescence Results.............................................

vi

38

LIST OF FIGURES
1.
2.

3.
4.
5.

Ouchterlony Double Diffusion Analysis Demonstrating the
Isotype of the Antibody Secreted by Hybridoma Clone H l2............

41

Indirect Immunofluorescence Microscopy Demonstrating the
Selective Binding ofH12 to YLDV Infected Owl Monkey
Kidney Cells.....................................................................

43

Indirect Immunofluorescence Microscopy Demonstrating H12
Binding Directed Against a Late YLDV Polypeptide.....................

46

Indirect Immunofluorescence Microscopy Demonstrating H12
Cross Reactivity with TPV....................................................

48

Autoradiogram of Immunoprecipitates with H12 Demonstrating
Precipitation of Two Polypeptide Chains.................................... 50

vii

INTRODUCTION

Poxviruses

Poxviruses are the largest and most complex ofall known animal viruses. The
family Poxviridae can be classified into two subfamilies: the Chordopoxvirinae
(infecting vertebrates), and the Entomopoxvirinae (infecting insects).

There are

eleven genera of the Poxviridae family. Viruses that are included in the same genus
are related both genetically and immunologically and share a common ultrastructure
and host range (reviewed in Moss, 1996).
Poxviruses have contributed significantly in the fields of both biomedicine
and molecular biology. Cowpox virus has been used to create a vaccine against
smallpox virus and vaccinia virus is used today as a vector for the insertion offoreign
genes in vaccine development through recombinant techniques (Mackett et al., 1982).
The entire replication cycle ofpoxviruses occurs in the cytoplasm oftheir host
cell, making them unique among DNA viruses. All species of poxviruses, except
members ofthe Yatapoxvirus genus, produce pocks on the chorioallontoic membrane
ofembryonated chicken eggs (Fenner, 1996).
Poxviruses are large, complex particles, oval or ''brick-shaped" in structure,
and measuring 300-400 nm x 170-260 nm. Deharven and Yohn (1966) showed that
thin sections under electron microscopy reveal an outer surface composed oflipid and
1
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protein surrounding a biconcave or dumbbell-shaped core. Analysis of vaccinia virus
demonstrates that the dry weight of the virion is 90 % protein, 5 % lipid, and 3.2 %
DNA (Smadel and Hoagland, 1942, Zartouw, 1964). The double-stranded, linear
DNA of poxviruses is found within the core unit. Interestingly, there are two forms
of viral particles observed during replication. The intracellular mature virions (IMV),
which contain a single inner membrane, and the extracellular enveloped virions
(EEV), which contain a second extracellular or outer membrane envelope (Payne,
1978)
Poxviruses are taken up by the host cell through an active process termed
pinocytosis (Joklik, 1968) and go through two cycles of uncoating. In the first
uncoating process, occurring immediately upon entry into the cytoplasm of the host
cell, the viral particle is converted to viral cores (Joklik 1964, Sarov and Joklik,
1972). It is within these viral cores that some early transcription occurs (Kates and
McAuslan, 1972, Daul and Kates, 1970a, Daul and Kates 1970b) coding for proteins
that are necessary for the second stage of uncoating and viral DNA replication
(Dubbs and Kit, 1964, Smith et al., 1989, Slabaugh et al., 1988, and Broyle, 1993).
This results in the release of naked viral DNA and initiation of viral DNA replication
(Sarov and Joklik, 1972). The viral DNA is replicated in organized areas in the
cytoplasm termed viral factories (Fenner et al., 1989). As infection proceeds, these
viral factories become larger. Viral assembly also occurs within the cytoplasm of the
host cell with two forms of infectious particles seen, those being the IMV and EEV
(Payne, 1978). EEV migrate to the cell surface along microfilaments (Hiller et al.,
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1981 ), fuse its outer layer with the host cell plasma membrane, and are released by
budding (Payne, 1978).
The cytopathic effect (CPE) that is observed from poxvirus infection is
dependent not only on the strain of the infecting virion, but also the type of host cell
that is infected. The general morphologic cytopathogenesis involves the rounding of
infected cells followed by granulation of the cytoplasm due to the developing viral
factories. Poxvirus infection also causes the host cell to rapidly alter its shape and
cytoskeletal organization (Traktman, 1991).
Tanapox Virus and Yaba-Like Disease Virus

Classification

Tanapox virus (TPV), yaba-like disease virus (YLDV) and yaba monkey
tumor virus (YMTV) are the three members comprising the Yatapoxviros genus.
Yatapoxviros genus viruses infect all primates, but cause disease primarily in non

human primates. TPV, YLDV and YMTV are related to one another based on size,
shape and ultrastructure. TPV is serologically related to YLDV, but restriction maps
of the viral genomes of TPV and YLDV reveal a difference in fragment patterns with
the restriction endonuclease Pstl (Downie and Espana, 1973, Kight et al., 1989).
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Epidemiology of TPV and YLDV

TPV was first isolated from a population of natives living within the Tana
River Valley in Kenya, Africa in 1962 (Downie et al. 1971). This epidemic was
associated with a period of extensive flooding in Kenya when the human population
together with their domestic and wild animals was crowded on small islands among
the floodwaters. In Zaire, cases are reported throughout the year, with the majority of
the cases being reported between the months of November and March (Jezek et al.,
1985) and in the township of Lisala, among persons living within 300 meters of the
Zaire River.
YLDV first gave rise to epizootics in three primate centers in the United
States in 1965-66, the National Center for Primate Biology, Davis, CA (Espana,
1971), the Oregon Regional Primate Center (Hall and McNulty, 1967; Nicholas and
McNulty, 1968), and the United States Air Force School of Aerospace Medicine,
Texas (Casey et al, 1967; Crandell et al, 1969). Between March of 1965 and
December 1968, 16 individuals, mainly animal handlers, developed the disease with
yaba-like disease virus being isolated from the lesions of three human cases (Espana,
1971). The viral isolates from the three locations have been reported as three separate
viruses: yaba-like disease virus (Espana, 1971), Oregon 1211 virus (Nicholas and
McNulty, 1968) and yaba-related virus (Crandell et al, 1969). Interestingly, the
infected monkeys in the Primate Centers of California, Oregon and Texas had all
been supplied by the same importer on whose overcrowded premises African and
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Asiatic monkeys had been housed in the same building. Because the disease affected
mostly Asiatic monkeys of the genus Macaca while African green monkeys were not
apparently susceptible, it has been suggested that the virus may have been transmitted
to the macaques from asymptomatic African monkeys (Downie and Espana, 1971;
Schmidt, 1970).

Morphology of TPV and YLDV Virions

TPV and YLDV have similar morphologies that are distinctive from YMTV
(Espana et al, 1971). Unlike TPV and YLDV, immature YMTV viruses are spherical
in shape and have an electron density only slightly greater than that of the
surrounding background (DeHarven and Yohn, 1966).
TPV virions are found to be enveloped at all times during the course of viral
replication (Fenner, 1990). Electron microscopic studies on TPV and YLDV virions
cultivated in embryonic rhesus monkey kidney (EMK) cells (Espana et al, 1971) and
CV-1 cells, show biconcave or dumbbell-shaped, DNA containing cores with lateral
bodies contained within the concavities. The mature particles also demonstrate a
double lipoprotein bilayer that is present on the virions found within both the intra
and extracellular spaces of the EMK cells.

6
Biological Similarities ofTPV and YLDV

TPV and YLDV have been shown to have similar biological properties
(Downie et al., 1971; Espana, 1966; Hull, 1968; McNulty et al., 1968). The lesions
caused by TPV and YLDV in monkeys were histologically identical and electron
microscopic studies have shown the changes produced in infected tissues culture cells
by TPV and YLDV to be similar (Espana et al, 1971). TPV and YLDV in CV-1 cell
cultures produced small, irregular plaques with dense borders. The density of these
borders seemed to result from cell foci formation by irregular retraction from the
culture dish.

The morphology of both virus-induced cell foci formation was

distinctive from that previously demonstrated by Downie and Espana (1973) for
YMTV. Early CPE observed at three days post infection, included the development
of cytoplasmic vacuoles. Nuclear vacuolization and intense granulation due to the
developing viral factories within the cytoplasm were noted at six days post infection
(reviewed in Knight et al., 1989).

Serological tests such as active immunity

experiments, complement-fixation tests, neutralization tests, and precipitation
experiments, have failed to demonstrate antigenic differences between
YLDV (Downie and Espana, 1971).

TPV and

7

TPV and YLDV Genomes

TPV and YLDV are both double stranded, linear DNA viruses.

By

calculation of the sum of the DNA digest fragment molecular sizes, the size of TPV
and YLDV virion DNA was established to be 145-kbp (Knight et al., 1989). Pstl and
BamHI restriction endonuclease patterns indicated that TPV and YLDV viruses are
closely related; however, they could be discerned as separate strains, quite distinct
from YMTV (Knight et al., 1989). While the complete sequence of YLDV has been
determined (Lee et al, 2001), only about 17% of the TPV genome has been cloned
(Neering, 1993). TPV Pstl digested fragments: F (9.0 kbp), H (6.6 kbp), J (5.1 kbp),
L (2.1 kbp), M (1.4 kbp), and N (1.1 kbp), were successfully cloned into pUC 19.
The Pstl-L fragment was completely sequenced, predicted amino acids and putative
open reading frames (ORFs) analyzed (Neering, 1993), with the other five fragments
having been recently sequenced (unpublished results).

Monoclonal Antibodies

History of Antibody Discovery

Bordet (1895) made an important discovery in 1895 when he found that the
clearing of a bacterial infection by a host involved two separable activities. One
activity (complement) did not require immunization, but was destroyed by treatment

8
of serum at 56 ° C for 30 min. The other required immunization but was stable to
heating to 56° C for 30 min. The latter activity was subsequently identified as
antibody. Bordet went on to show that lysis ofred blood cells by immune serum was
functionally equivalent to lysis of bacteria by immune serum and complement
(Bordet 1898).

Although Bordet was the first to use the term "antibody'', the

discovery of antibodies is generally accredited to von Behring and Kitasato (reviewed
in Bulloch, 1938; Cohen and Porter, 1964; Silverstein, 1989). In 1890, they showed
that immunity to diphtheria and tetanus is due to antibodies to toxins secreted by
these organisms.
The knowledge gained about antibodies from Behring and Kitasato was put
into clinical use almost immediately following its discovery. In 1891, a child dying
of diphtheria was given immune serum and made a recovery that had not been
previously reported (Bulloch, 1938).

Although the serum sometimes provided

dramatic improvements, there were also side effects of the serum administration.
Today we know this side effect as anaphylaxis, which is caused by the development
oflarge amounts antigen-antibody complexes throughout the recipient's body.

BriefHistory ofDevelopment ofMonoclonal Antibody Technology

In 197 5 Kohler and Milstein were the first to describe development of hybrid
cells that produced monoclonal antibodies of predefined specificity (Kohler and
Milstein, 197 5). They described the derivation ofa number oftissue culture cell lines
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that secreted anti-sheep red blood cell (SRBC) antibodies. The cell lines were made
by a fusion of a mouse myeloma with mouse spleen cells taken from an immunized
donor.
Each immunoglobulin chain produced from a hybrid cell results from the
integrated expression of one of several variable (V) and constant (C) genes coding
respectively for its V and C sections from the genome of each parental cell. Each cell
expresses only one of the two possible alleles (Milstein and Munro, 1973). When two
antibody-producing cells are fused, the products of both parental lines are expressed
(Cotton and Milstein, 1973; Schwaber and Cohen, 1974), and although the light and
heavy chains of both parental lines are randomly joined, no evidence of scrambling of
the V and C sections is observed (Cotton and Milstein, 1973). The results from
Kohler and Milstein' s work provided the background for the derivation and
understanding of antibody-secreting hybrid lines in which one of the parental lines is
an antibody-producing spleen cell (Kohler and Milstein, 1975).

Myeloma Cells: Non-Secreting Immortal Fusion Partner

In 1959, it was accidentally discovered that peritoneal irritants could cause the
development of myelomas in BALB/c mice (Merwin and Redmon, 1963).

A

myeloma is the tumor caused by malignantly transformed antibody-secreting cells.
Compared with other gene products, there is a rather high frequency of variants and
deletions in immunoglobulin synthesis by cultured myeloma cells (Adetugbo et al.,
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1977) and the loss of heavy chain production is particularly common (Cotton et al.,
1973) due to deletions in the VH gene (Thammana, 1994). The use of myeloma cell
lines that produced immunoglobulin product as one of the fusion partners in the
production of hybrid cells reduced the quality of the overall yield of the desired
antibody (Cotton et al., 1973). This problem was overcome when the clone P3-X63Ag8.653, which did not express heavy or light chains, was discovered in 1979
(Kearney et al., 1979). The use of this particular clone in fusion experiments allows
for the product to be completely of antibody-producing cell origin (Kearney et al.,
1979).

Techniques for Cell Fusion and Hybridoma Selection

Electroporation (Steenbakkers et al., 1993; Zimmermann et al., 1990) and
electro-acoustic (Bardsley et al., 1990) techniques are alternative techniques that are
useful when low numbers of specific B cells are available for fusion. A more
traditional method for cell fusion is the treatment of the two cell lines to be fused with
either Sendai virus or a high frequency polyethylene glycol (PEG). When cells are
treated with either of these two agents, their membranes fuse and multinucleate cells
called heterokaryons are formed (Ringertz and Savage, 1976; Abbott and Povey,
1995). At the next cell division, the nuclei of the heterokaryons fuse, and the
daughter cells possess a more or less equal share of the genetic material. The exact
mechanism of the fusion is still poorly understood (Zimmerberg et al., 1993). An
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attempt to understand the mechanism by which PEG promotes cellular fusion
(Wojcieszyn et al., 1983) suggests that the coordinate action of two distinct
components is necessary for fusion as mediated by PEG. Presumably, the polymer
itself promotes close apposition of the adjacent cell membranes, but the additives
contained in the commercial PEG provide the fusion stimulus.
When a cell mixture, cell A/cell B, is subjected to reagents that promote
fusion there are three possible hybrid cells that can be formed: A-A, A-B and B-B.
Thus, if it is desired to produce the A-B fusion as a long-term hybrid cell line from
two cells, a selection procedure is required. The most common selection procedure is
that devised by Littlefield (1964). Briefly, this selection procedure depends on the
fact that when the main biosynthetic pathway for guanosine is blocked by the folic
acid antagonist aminopterin, there is an alternative "salvage" pathway in which the
nucleotide metabolites hypoxanthine or guanine are converted to guanosine
monophosphate via the enzyme hypoxanthine guanine phosphoribosyl transferase
(HPRT). Cells lacking HPRT die in a medium containing hypoxanthine, aminopterin
and thymidine (HAT medium) because both the main and salvage pathways are
blocked. However, an HPRT- (myeloma) cell can be made to grow in HAT medium
if it provided with the missing enzyme by fusion with an HPRT+ cell (B-cell from an
immunized donor).
Lyon (1964) and Littlefield (1964) found, due to the fact that myeloma cells
will spontaneously mutate to form HPRT+ cells, it is essential to select for the proper
myeloma fusion partner prior to cellular fusion by selection of HPRT- myeloma cells
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with the use of the toxic base analogue 8-azaguanine, which is incorporated into the
DNA via HPRT. Because the salvage pathway is not normally essential for cell
survival, mutants that lack HPRT will continue growing, while cells that possess
HPRT will die.

Applications of Monoclonal Antibodies

Since the development of the technique by Kohler and Milstein in 1975, there
have been many monoclonal antibodies developed by a vast number of different
investigators to assist in their studies and diagnoses of novel systems and chronic
diseases.

This section will outline only a few in order to provide a better

understanding of the many utilizations that monoclonal antibodies can provide and
lend to the reader an appreciation of the technique that resulted in Kohler, Milsrtein
and Jerne being awarded the Nobel Prize in Immunology in 1984.
Monoclonal antibodies are useful research tools in the analyses of structure
and function of microbial and other proteins, and have become powerful reagents in
the diagnosis and treatment of infection and biomedical research. Antibody-based
specific identification and detection of microorganisms, including viruses, and their
respective antigens form the basis of a large array of techniques that are indispensable
to almost all areas of basic research and are becoming more widely used.
The power that is provided by antibody-based techniques can be increased
with the use of monoclonal antibodies as opposed to polyclonal antisera. Monoclonal
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antibodies have not completely replaced polyclonal antisera in many applications of
the antibody-based technique, but their availability has greatly expanded the scope of
antibody usage.
An example of the superiority of monoclonal antibodies over polyclonal
antisera is in the analysis of functional membrane-proteins such as cytokine receptors,
adhesion molecules, signal transduction and enzymes.

Monoclonal antibodies

developed against human leukocyte differentiation antigens (Knapp et al., 1989;
McMichael et al., 1987; Schlossman et al., 1994) have been used to identify and
characterize more than at least 100 new molecules, which were previously unknown.
Monoclonal antibodies can also be used to stabilize molecules by forming
antigen-antibody complexes that can then be used for structural studies. Moore et al.,
(1993) used monoclonal antibodies to resolve the structure of the viral surface
envelope glycoprotein gp120 of human immunodeficiency virus (HIV).
Grose et al. (1983) used the technique to develop monoclonal antibodies
against the varicella-zoster virus (VZV).

They describe three prominent

glycoproteins- gp62, gp98 and gpl 18, which are coded for by VZV from infected
cells. They demonstrated the development of four monoclonal antibodies, which
reacted with both gp62 and gp98, and one that reacted with gpl 18. Also, when
assayed for neutralizing activity, the secretory product of the single anti-gp118
hybridoma, but not the supematants from the four anti-gp-62/98 clones, inhibited
VZV plaque formation by greater than 80%. Thus, Grose et al. (1983) used a
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monoclonal antibody to show that at least one of the glycosylated antigens ofVZV is
a determinant that elicits neutralizing activity ofVZV infection.
Tang et al. (2001) have reported the development of a new treble-coated
enzyme-linked immunoadsorbent assay (ELISA) kit for detecting hepatitis B virus
(HBV) surface antigen subtypes a, d and r (HbsAg-a, -d, -r) through the establishment
of four hybridoma cell lines. Their results indicated that this new kit was more rapid
and sensitive than other current ELISA-based kits coated with a single monoclonal
anybody (e.g., anti-HbsAg-a).

These results show that a series of monoclonal

antibodies, targeting different antigens on the same pathogen, can be used in
conjunction with one another to increase the accuracy of results gathered from such
tests as ELISAs.
Aside from the role that monoclonal antibodies can play in the analysis and
detection of viral pathogens, they can also be used in the analysis of signal
transduction. Houlden et al. (1991) have generated an anti-mouse class I reactive
monoclonal antibody that is capable of activating T cells in the presence of cofactor
PMA, as assayed by both interferon-y production and cellular proliferation. This
monoclonal antibody also recognizes multiple human class I molecules. The data
gathered by the investigators have demonstrated the potential for the involvement of
class I molecules, which are usually not considered as activation antigens, in the
signal transduction pathway ultimately leading to the activation of T cells in the
immune response.
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Monoclonal antibodies have also proven to be a useful tool in the study of
organ system structure and function. Quaroni (1983) used Kohler and Milstein's
technique to develop nineteen monoclonal antibodies directed against intestinal brush
boarder membrane proteins.

Ten of the antibodies were shown to specifically

immunoprecipitate surface-membrane proteins. . Two antibodies were found to be
specific for sucrase-isomaltase, one for an aminopeptidase, two for an isoenzyme of
alkaline phosphatase that is exclusively in the proximal small intestine, and one for
maltasae-glucoamylase. These monoclonal antibodies should prove to be invaluable
tools for the study of the biosynthesis of cell-surface proteins, the fetal and postnatal
development of specific intestinal functions, and the process of cell differentiation in
the intestinal epithelium.
The use of monoclonal antibodies directed against cancer cells has found
increasing usefulness in recent years. Relative tumor specificity and a lack of
significant toxicity, together with the ability to link radionuclides without significant
deterioration of biological behavioral characteristics such as immunoreactivity, have
enabled widespread use of radiolabeled monoclonal in several malignancies,
including malignant melanoma and breast cancer (Divgi and Larson, 1989; Memo,
Monteagudo, and Neumann, 1991).
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Conclusions

Having demonstrated the biologic and genomic similarities demonstrated
between TPV and YLDV, also called Oregon 1211 virus and yaba-related virus,
coupled with the fact that the monkeys from which YLDV was isolated from
outbreaks in the primate center of Oregon, Texas, and California were received from
the same importer, it stands to reason that these are simply different strains of the
same virus. The nomenclature of Tanapox virus- Kenya strain and Tanapox virus
OrTeCa strain is being suggested by our laboratory as names that would simplify the
classification of this virus.
Given the power of the hybridoma technique as an experimental approach for
the analysis of complex biological systems, it was the intent of this project to develop
a bank of monoclonal antibodies that could be used to demonstrate the conservation
of individual antigens of both TPV and YLDV in an effort to further identify these
viruses as different strains of the same virus. Also, since TPV and YLDV are related
to smallpox virus, but with greatly reduced virulence, a bank of monoclonal
antibodies directed against these viruses could prove to an invaluable tool in the study
of these viruses as models of the virus-host interaction.

MATERIALS AND METHODS

Virus, Cells and Reagents for Virus Cultivation

Owl monkey kidney (OMK) cells (American Type Culture Collection,
Rockville, MD) were grown in RPMI 1640 (Life Technologies, Grand Island, NY)
supplemented with 10.0 % (v/v) newborn calf serum (NBCS) (Life Technologies),
2.0 mM L-Glutamine, and antibiotics (100 units/ml penicillin G sodium, 100 µg/ml
streptomycin sulphate and 0.25 µg/ml amphotericin B) (Life Technologies)[OMK
growth medium]. OMK cells were maintained in RPMI 1640 supplemented with 2.0
% (v/v) NBCS, 2.0 mM L-Glutamine, and antibiotics (maintenance medium). Yaba
like disease virus (YLDV) (American Type Culture Collection) was cultivated in
OMK cell monolayers maintained in maintenance medium at 37 ° C with 5 % CO2 •

Virus Concentration

Confluent Monolayers of OMK cells were infected with YLDV at 1.0-2.0
plaque forming units per cell (pfu/cell). Following adsorption for 1.0 hour on a
rocker table at room temperature (RT), infected cells were maintained in maintenance
medium and incubated for 10-14 days. Infected cells were harvested using a sterile
17
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cell scraper (S/P®Brand dispo® Cell Scraper, Baxter, McGraw Park, IL) and collected
as lX virus mixture. The lX virus mixture was then centrifuged (approximately 100
x g, Damon IEC PR-6000 at 2000 rpm) at 4.0° C for 20.0 min. The supernatant from
this centrifugation was then saved and each cell pellet was then resuspended in 1.0 ml
maintenance medium and subjected to three cycles of freeze/thaw (ethanol and CO2 (S)
mixture was used to freeze with 37.0° C H20 bath used to thaw) to release all
intracellular virus particles. OMK cellular debris was removed from each sample by
centrifugation (100 x g, Damon IEC PR-6000, at 2000 rpm) at 4.0°C for 20.0 min.
The supernatant from these samples and that saved from the previous centrifugation
of the lX virus mixture was then centrifuged at 85,000 x g, (Beckman Optima XL100K ultracentrifuge; Ti-45 rotor at 30,000 rpm) for 1.5 hours at 4.0° C. Each virus
pellet was then resuspended overnight in maintenance medium to a final
concentration on 100X and quantified by viral plaque assay (Essani, 1982). Briefly,
OMK cells monolayers grown in 6-well plates were infected with 200.0 µI/well of
serial ten-fold dilutions of l00X YLDV, with each dilution being plated in duplicate.
Virus was adsorbed at RT for 1.0 hour on a rocker table. Following adsorption, 2.5
ml of overlay medium [maintenance medium with 0.5 % methyl cellulose (4000
centipoises) (Fisher Scientific, Pittsburgh, PA)] was added to each well and the plates
were then incubated at 37.0° C with 5.0 % CO2 for 10-14 days. Medium was then
carefully aspirated from each well, without disturbance of the monolayer, and 1.0 ml
of 0.1 % crystal violet and 10.0 % formaldehyde in deionized water was then added
to each well to fix and stain the cells for 30.0 min at RT. Plates were then rinsed with
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distilled water and allowed to dry. Plaques were counted to determine pfu/ml by the
following formula: [pfu = ((number of plaques in well-A + plaques in well-B) / 2) x
dilution factor for that duplicate of wells], then [number pfu (200.0 µl)] x 5 = 1.0 ml
pfu.

Immunization

Authorization for the use of an animal model for this research study was
obtained under IACUC protocol number 95-08-01. Under this protocol, no adjuvant
was used to enhance the immune response. Accordingly, female, BALB/c mice, 4-6
weeks old (Charles River Laboratories, Portage, Ml) were immunized with YLDV
though a series of five weekly 100.0 µl, intraperitoneal (IP) injections of lO0X
YLDV. The final or booster injection was administered four days prior to the fusion.
Each mouse was monitored daily for any complications due to the immunization
protocol.

Fusion

Myeloma Cells and Reagents

Mouse plasmacytoma, P3x63.Ag8.653 (American Type Culture Collection)
(myeloma cells) cells were grown in RPMI 1640 supplemented with 20.0 % (v/v)
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HY-CLONE, fetal bovine serum, (PBS) (Sterile Systems, Inc, Logan, UT), 2.0 mM
L-Glutamine, and antibiotics (hybridoma growth medium) at 37.0° C with 5.0 % CO2.
Two weeks prior to the fusion date, the myeloma cells were grown in myeloma
growth medium supplemented with 6.6x10-2 M 8-Azaguanine (Sigma, St. Louis, MS)
for selection of HPRT (-) (Littlefield, 1964) cells for one week, about 3-4 growth
cycles. Following this one-week treatment with 8-Azaguanine, the myeloma cells
were once again grown in myeloma growth medium without 8-Azaguanine for one
week prior to the fusion date. The cells were fed one day prior to the fusion to ensure
that the cells were in the exponential growth phase for the fusion.

Myeloma Cell Quantification

The P3x63.Ag8.653 cells were counted using a hemocytometer in standard
fashion to ensure the correct ratio of immunized splenocytes to myeloma cells, 10: 1
respectively (Zola, 1995). Briefly, the cells were maintained in a 75 cm2 tissue
culture flask, kept upright, containing 5.0 ml/flask ofhybridoma growth medium. The
flask was then gently shaken to resuspend all cells and a sterile, glass, pasture pipette
was then dipped into the solution with the forefinger being placed over the end ofthe
pipette following emersion of the pipette tip to create a vacuum, as to keep solution
within the pipette. A glass cover slip was then placed of the counting grid of the
hemocytometer and the pipette was placed along the edge of the cover slip to allow
diffusion ofthe solution under the slip and subsequently over the counting grid. The

21
counting grid consists of four equally partitioned square areas separated into
quadrants by a series of lines within the overall grid area. All individual cells, not
clusters, that lie on the upper and right boundaries of each individual partition are
counted to calculate a sum for each of the four square areas. The following formula
is then used to calculate the total number of cells/flask:
{[(sum quad l )+(sum quad 2)+(sum quad 3)+(sum quad 4)]/4}= avg. cell
number/quad; (avg. cell number/quad) x 104= number of cells/ml; [(number of
cells/ml) x (total volume per flask)]= total number of cells/flask.

"Feeder Cells"

A modification to the original procedure (Fazekas and Scheideggar, 1980) for
the development of "feeder cells" was used. "Feeder cells" were obtained from a
non-immunized, female, BALB/c mouse 24.0 hours prior to the fusion. A 1.0 ml
injection of sterile, phosphate buffered saline (PBS) (137.0 mM NaCl, 2.7 mM
Na2HPO4, 1.4 mM KH2PO4; pH 7.4) was administered intraperitoneally to the mouse
to be used for the harvesting of the "feeder cells". Following the injection of PBS,
the abdomen was massaged to wash the peritoneal cavity. The mouse was sacrificed
by cerebral dislocation and the skin of the abdomen was retracted exposing the
peritoneum. A sterile, glass, pasture pipette, plugged with cotton, was then used to
remove the PBS from the peritoneal cavity. The PBS was then added to 50.0 ml
conical centrifuge tube containing 49.0 ml hybridoma growth medium, with this
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solution then used to perform five subsequent washes of the peritoneal cavity. The
centrifuge tube was then vortexed and it's contents poured into a sterile petri dish.
An eight-channel pipette (Titertek® digital multichannel pipette 50-200µ1, Flow
Laboratories, Finland) was then used to distribute 100.0 µl into each well in five
separate polystyrene, flat-bottom, 96-well tissue culture plates (Corning Glass Works,
°

Corning, NY). The "feeder cells" were then incubated overnight at 37.0 C with 5.0
%CO2.

Fusion Protocol

Modifications to the original fusion protocol (Kohler and Milstein, 1975) were
made and the procedure completed as outlined. An immunized BALB/c mouse was
sacrificed by cerebral dislocation and soaked in 70.0 %ethanol for 5.0 min. A 4.0 cm
incision was then made along the centerline of the abdomen exposing the peritoneal
cavity. The spleen was then located and a splenectomy performed by cutting the
Splenorenal ligament, Splenic artery, Splenic vein and all connective tissue. The
excised spleen was then transferred into a 50.0 ml conical centrifuge tube containing
5.0 ml of RPIM 1640 supplemented with antibiotics only (serum-free medium) at
37.0 ° C. The spleen was then placed on a sterile, stainless steal mesh covering a
400ml sterile, glass beaker. A rubber policeman was then used to homogenize the
spleen to separate all splenocytes from residual fat and fascia. The stainless steel
°

mesh was then washed with an additional 25.0 ml serum-free medium at 37.0 C.
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The contents of the beaker (serum-free medium and immunized splenocytes) along
with a flask of myeloma cells (prepared as previously discussed) were added to a 50.0
ml conical centrifuge tube and centrifuged (75 x g, Damon IEC HN-SII, at 1500 rpm)
at RT for 10.0 min.

The supernatant was then removed and 25.0 ml serum-free

°

medium at 37.0 C was then added to resuspend the pellet through gentle inversion.
The contents of the tube were once again centrifuged (75 x g, Damon IEC HN-SII, at
1500 rpm) at RT for 10.0 min. This was cycle was repeated one more time for a total
of three wash cycles.

Following the third wash of the immunized

splenocyte/myeloma cell pellet, 100.0 µ1 of serum-free medium was left in the
centrifuge tube to resuspend the pellet. A volume of 1.0 ml of polyethylene glycol
(PEG) 4000 (Life Technologies) at 37.0 ° C was then added to the resuspended cells
over the course of 1.0 min. A slow dilution of the PEG was then carried out with
serum-free medium over the next 21.0 min as follows: 10.0 ml over 10.0 min; 10.0 ml
over 5.0 min; 10.0 ml over 3.0 min; 10.0 ml over 2.0 min; and 9.0 ml over the last 1.0
min, for a total dilution of 49:1, serum-free medium to PEG respectively. This
mixture was then centrifuged (75 x g, Damon IEC HN-SII, at 1500 rpm) at RT for
10.0 min. The resultant supernatant was then discarded and the pellet of fused cells
was then resuspended in 50.0 ml of hybridoma growth medium. The fused cellular
suspension was then poured into a sterile petri dish. At this time, the 96-well dishes
containing the "feeder cells" were removed from the incubator and the medium
aspirated from each well. An eight-channel pipette was then used to distribute 100.0
µ1 of the suspension to each well. The 96-well dishes were then incubated for 24.0
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hours at 37.0 ° C with 5.0 % CO2. Following 24.0 hours, an additional 100.0 µ1 of
hybridoma growth medium supplemented with 8x lf 7 M aminopterin, 3.2x10-5 M
f

thymidine, and 2x104 M hypoxanthine (HAT) (Life Technologies) (2X selection
medium) was added to each well (Littlefield, 1964). All subsequent medium changes
that were required for each individual well, within the first three weeks following the
fusion procedure, were completed by removal of 100.0 µ1 of well supernatant
followed by the addition of 100.0 µ1 of hybridoma growth medium supplanted with
4x10-7 M aminopterin, l .6xlf 5 M thymidine, and l x104 M hypoxanthine (HAT)
f

(selection medium). All medium changes within wells following the first three weeks
were completed with hybridoma growth medium.

Hybridoma Screening Assay

Collection of Hybridoma Supernatant

All wells were observed daily for hybridoma colony formation. Once a viable
colony had been discovered, it was monitored daily for necessary medium changes;
medium was considered to be depleted of nutrients upon color change from red to
orange/yellow of the indicator- Phenol Red contained within the RPMI 1640. Upon
color change within any given well, 100.0 µ1 of the well's supernatant was removed
and stored at 4.0 ° C with 100.0 µ1 of either selection medium or hybridoma growth
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medium, dependent upon the time that past following the fusion (see above- fusion
protocol), being added the well.

Development of Cover Slips

OMK cell monolayers were grown on 25 cm2, glass cover slips (Corning),
sterilized by autoclaving, in 100 cm2 tissue culture dishes in OMK growth medium.
OMK cells were then infected at 50.0 pfu/cell with YLDV in standard fashion (see
above- virus concentration) and maintained in maintenance medium until 80-90 % of
all cells demonstrated cytopathic effect (CPE), 5-7 days post infection. Maintenance
medium was then aspirated and 100.0 % ethanol at -80.0° C was then added to each
plate for 30.0 sec for cell fixation. Following fixation, the ethanol was removed and
the fixed cover slips were stored in PBS at 4.0° C. Mock cover slips were fixed in
identical fashion following the development of confluent monolayer and mock
infection with maintenance medium for 5-7 days.

Indirect Immunofluroescence (IF) Assay

A hybridoma colony was screened for anti-YLDV antibody production once
the colony had reached 50-70 % confluence within the well it was contained.
Supernatant was removed from the well in 100.0 µ1 quantities to provide adequate
volume for screening against both uninfected and YLDV infected OMK cells. Cover
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slips were first washed three times for 5.0 min intervals at RT with PBS with 0.1 %
gelatin (BioRad, Richmond, CA) pH 7.3, to block any non-specific protein binding.
Each cover slip, both an uninfected and infected, was covered with 50.0 µI of the
hybridoma of interest's supernatant and incubated at 37.0° C in a humidified
incubator for 2.0 hours. Each cover slip was then washed three times for 5.0 min
intervals at RT with PBS, pH 7.3 to remove all non-bound protein. Following this
washing cycle 50.0 µl of an anti-mouse lgG (whole molecule) Fluroescein
Isothicyanate (FITC) conjugate (anti-mouse lgG-FITC) developed in goat (Sigma),
diluted 1: 100 in PBS with 0.1 % EIA grade gelatin (BioRad), ph 7.3 was then added
to each cover slip followed by an additional two hour incubation period at 37.0° C in
a humidified incubator. Each cover slip was again washed three times for 5.0 min
intervals at RT with PBS, pH 7.3 to remove all non-bound secondary antibody. Each
cover slip was then mounted on a glass slide (Sigma) with 20.0 % glycerol in PBS,
pH 7.3 and sealed with "Built-in Topcoat" (Cover Girl, Hunt Valley, MD). Slides
were then viewed on a Nikon MICROPHOT-FXA (Nikon, Tokyo, Japan), with filter
set: excitation filter 450-490 nm and barrier filter 520 nm, using a super high pressure
mercury lamp (Model HB-10101AF, Nikon) for positive staining results.
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Maintenance ofPositive Clones

Cloning by Limiting Dilution

Slight modifications to the original procedure (Lefkovits and Wadlmann,
1979) were implemented. All hybridoma clones that produced positive IF results
were cloned to ensure the presence ofonly one producing clone. Positive clones were
suspended through pipetting and plated out in serial twofold dilutions in 200.0 µ1
cultures in 96-well dishes (Corning). The group in which about halfofthe wells had
no growth was considered to contain the progeny ofsingle cells (Goding, 1996). This
group was then rescreened through IF for antibody production. All hybridoma clones
that produced a second positive IF result were then recloned through the same
procedure for cloning by limited dilution. Colonies were allowed to grow in 200.0 µ1
of myeloma growth medium until 70 % confluence was achieved within the well.
The cells of four separate wells from a 96-well dish, displaying 70 % confluence,
were then resuspended and transferred to a 24-well dish (Coming) and grown in 1.0
ml hybridoma growth medium. Again, once 70 % confluence was achieved in these
wells, the cells from two ofthese wells resuspended and transferred to a 12-well dish
(Corning) and grown in 2.0 ml ofhybridoma growth medium. Finally, the cells from
an individual well in a 12-well dish at 70 % confluence were then transferred to a 75
cm2 tissue culture flask and grown in total volume of 5.0 ml hybridoma growth
medium.
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Cryopreservation ofHybridoma Cells

Positive hybridoma cells were grown in suspension culture in 75 cm2 tissue
culture flasks in 5.0 ml of hybridoma growth medium. Each flask to be frozen was
fed the day before the freezing procedure to ensure that the cells were in the
exponential growth phase; 2.5 ml of the supernatant was removed and 2.5 ml of fresh
hybridoma growth medium at 37.0° C was added. The flask was then incubated for
24.0 hours at 37.0° C with 5.0 % CO2. The cells were then resuspended in the flask
by pipetting and transferred to a 15.0 ml conical centrifuge tube and centrifuged (75 x
g, Damon IEC HN-SII, 1500 rpm) at RT for 10.0 min. The supernatant was then
removed and the cells were resuspended in 1.0 ml of hybridoma growth medium
supplemented with 10.0 % sterile dimethyl sulfoxide (DMSO) (freezing medium).
The cells were then transferred to a 1.2 ml freezing vial (Gibco, Grand Island, NY),
placed in a freezing container (Cryo 1 C Freezing Container, Nalgene, Rochester,
NY), to achieve a -1.0° C/min rate of cooling, and stored in a -80.0° C freezer for
24.0 hours.

Following this 24.0 hour period, the cells were then immediately

transferred into holding racks and immersed in N2 for preservation.

Test of Cryopreserved Hybridoma Viability

Three days following initial cryopreservation, a freezing vial containing the
hybridoma of interest was removed from N2 (I) and immediately transferred to a 37 .o·
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C water bath and thawed for 3.0 min. Toe contents of the tube were then diluted in
19.0 ml hybridoma growth medium at 37.0 ° C in 75 cm2 tissue culture flask and
incubated at 37.0 ° C with 5.0 % CO2 for 48.0 hours. The viability ofhybridoma cells
was then visually assed following the 48.0 hour period. Toe supernatant from
hybridoma clones thawed following cryopreservation was also tested for antibody
production through immunofluroescence and immunodiffusion.

Hybridoma Characterization

Hybridoma Supernatant Concentration

Supernatant from hybridoma clones that were found to give initial positive IF
results was concentrated 25X using a Minicon® B-15 Clinical Sample Concentrator
(Millipore, Bedford, MA) thorough standard technique. Briefly, each sample was
prefiltered through Whatman No. 1 filter paper. A glass pasture pipette was then used
introduce the sample into the sample well and allowed to adsorb overnight. Each
sample well was able to concentrate ~5.0 ml hybridoma supernatant to a final
concentration of ~25X. Following, overnight adsorption, each sample was removed
and stored at 4.0° C for later use in characterization experiments.
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Indirect Immunofluroescence (IF) Assay and Digital Imaging

All hybridoma clones that were found to have initial positive staining results
were then taken though IF assays in triplicate. Three sets of cover slips were set for
each clone as follows: 1) uninfected cells treated with hybridoma supernatant as
primary antibody and anti-mouse IgG-FITC as secondary antibody; 2) infected cells
treated with hybridoma supernatant as primary antibody and anti-mouse IgG-FITC as
secondary antibody; and 3) infected cells treated with anti-mouse IgG-FITC only.
MetaMorph imaging software- version 4.1. 7 (Universal Imaging Corporation,
Downingtown, PA) together with a Nikon MICROPHOT-FXA (Nikon, Tokyo,
Japan) was then utilized to obtain digital pictures of all slides through IF, using a
super high pressure mercury lamp (Model HB-10101AF, Nikon), and differential
interference contrast (DIC) microscopy.

Hybridoma Isotype Determination- Immunodiffusion (ID) Assay

Ouchterlony double diffusion technique was used to determine the heavy
chain isotype of all antibodies produced by a hybridoma producing positive IF results.
A solution 1.0 % (w/v) agar and 0.01% (w/v) sodium azide in deionized water was
heated to 95.0° C in microwave oven, plated on a glass slide and allowed to cool and
form an agar slab.

An outline was then determined to have six outer wells

surrounding one center well all equal distance- ~1.5 cm. A mouse monoclonal
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antibody isotyping kit (Sigma) was then used per protocol. Briefly, 10.0 µl of the
concentrated hybridoma supernatant was added to the center well with 5.0 µl of each
of the isotyping reagents- anti-mouse IgG l , anti-mouse IgG2a, anti-mouse IgG2b,
anti-mouse IgG3, anti-mouse IgA, and anti-mouse IgM; being added to the outer
wells. The slide was then incubated at 37.0° C in a humidified incubator for 24.0
hours to allow for diffusion of all reagents. Following incubation, the slide was
removed from the incubator and placed in PBS at RT for 24.0 hours at RT to elute all
non-conjugated protein. The slide was then covered with a moist paper towel and
allowed to dry for and additional 24.0 hours at RT. Once the agar had completely
dried, an agar staining solution (0.1% Coomassie Brilliant Blue in deionized water)
was added to the slide for 5.0 min for protein staining. Following staining, the slide
was rinsed with deionized water and placed in destaining solution (5.0 % methanol,
7.0 % glacial acetic acid in deionized water) for 10.0-15.0 hours at RT. The slide was
then removed from the destaining solution and allowed to air dry.

Immunoprecipitation of Viral Antigen by Sodium Dodecyl Sulphate Polyacrylamide
Gel Electrophoresis
Preparation ofRadiolabeled Viral Antigen

OMK cell monolayers- consisting of 5.2x105 cells (Mediratta, 1997), grown in
60 mm2 tissue culture dishes (Coming), were infected with 200.0 µl of 1OOX YLDV
at a multiplicity of infection of ~50.0 pfu/cell until 80-90 % of all cells displayed
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CPE, 5-7 days post-infection. A mock set OMK cell monolayers in 60 mm2 dishes
was also maintained in maintenance medium for 5-7 days. Once 80-90 % of all
infected cells displayed CPE, the medium was aspirated from each dish and replaced
with maintenance medium containing 12.5 µCi/ml [ 14C]-L-amino acid mixture
(specific activity 50.0 mCi/mmol per carbon atom; ICN Biomedicals, Inc, Irvine, CA)
°

and incubated for 18.0 hours at 37.0 C with 5.0 % CO2. Following incubation, cells
were scrapped using a sterile cell scrapper (SIP®Brand dispo® Cell Scraper, Baxter,
McGraw Park, IL), transferred into a 15.0 ml conical centrifuge tube and centrifuged
(75 x g, Damon IEC HN-SII at 1500 rpm) at RT for 10.0 min. Supernatant was
°

collected and stored at 4.0 C. The cell pellets were then resuspended in 100.0 µI of
1.0 % (v/v) Nonidet P40 (NP-40) for 5.0 min on ice to lyse plasma membrane. Low
speed centrifugation (approximately 15 x g, Damon IEC HN-SII at 300 rpm) was then
carried out for 5.0 min to remove nuclei. A 95.0 µI volume of the supernatant was
then removed as not to resuspend the nuclear pellet. A 5.0 µI aliquot was then added
to 25.0 µI of dissociation buffer (DB) [0.0625 M Tris-HCI (pH 6.8), 2.3 % (w/v)
sodium dodecyl sulphate (SDS), 10.0 % (w/v) glycerol, 5.0 % (v/v) 2mercaptoethanol (ME) and 0.001 % bromophenol blue] for running of whole protein
preparation on gel. A 2X Immunoprecipitation buffer (IPB) (20 mM Na2PO4 pH 7.4,
0.3 M NaCl, 2.0 % deoxycholate, 2.0 % triton X-100) was added to the supernatant in
a 1: I, (v:v) ratio ofNP-40: IPB to give the final immunoprecipitation solution (IPS) .
°

The samples were then solubilized in a water bath at 37.0 C for 30.0 min. Following
heating, samples were prepared, in duplicate, for immunoprecipitation as follows: 1)
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45.0 µ1 IPS with 45.0 µ l 25X hybridoma supernatant; 2) 50.0 µ1 IPS with 50.0 µ1 of a
1:100 dilution of anti-mouse lgG2 antibody isotype reagent (anti-mouse IgG2)
(Sigma), to control for non-specific binding to antibody molecules. These samples
were then allowed to immunoprecipitate for 24.0 hours in a 37 .o· C water bath. After
24.0 hours, 20.0 µ1 of a 1:50 dilution of an anti-mouse lgG (whole molecule) (Sigma)
was added to one of the replicates from each of the two sets of immunoprecipitation
samples, with the other replicate receiving the addition of 20.0 µ1 Protein A/G PLUS
Agarose: sc-2003, prepared per protocol, (Santa Cruz Biotechnology, Inc., Santa
Cruz, CA) and incubated in a water bath at 37.0 ° C for 4.0 hours. The samples were
then centrifuged (Brinkman 5415C, at 12,000 x g) for 20.0 min at RT.

The

supernatant was removed and stored at 4.0 ° C. The pellet was then washed three
times with 0.85 % (w/v) NaCl in deionized water with subsequent centrifugation
(Brinkman 5415C, at 12,000 x g) for 20.0 min between each wash. Each pellet was
then resuspended in 30.0 µ1 of DB and heated to 100.0 ° C for 3.0 min for loading
onto SDS-PAGE gel. Mock samples were prepared in identical fashion of YLDV
infected samples.

SDS-PAGE Resolution of Viral Antigen

Radiolabeled immunoprecipitates from both YLDV infected and mock OMK
cells were resolved by electrophoresis on an 11.5 % polyacrylamide gel [29.2 %
(w/v) acrylamide: 0.8 % (w/v) bisacrylamide] as described by Essani and Dales
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(1979). Briefly, the upper or stacking gel consisted of consisted of 6.0 ml distilled
water, 2.5 ml upper gel buffer (0.5 M Tris-Base, 0.4 % (w/v) SDS, pH 6.8), 1.5 ml of
30.0 % acrylamide (29.2 % (w/v) acrylamide, 0.8 % (w/v) bisacrylamide), 30.0 µI of
10.0 % (w/v) ammonium persulphate and 10.0 µI of TEMED (N, N, N', N' tetra
methyl ethylene). The lower or separating gel consisted of10.7 ml deionized water,
7.5 ml lower gel buffer (1.5 M Tris-Base, 0.4 % (w/v) SDS, pH 8.8), 11.5 ml 30.0 %
acrylamide, 300.0 µ1 of10.0 % (w/v) ammonium persulphate and 15.0 µI ofTEMED.
The lower gel was poured and allowed to polymerize for 1.0 hour. A comb was then
inserted and the upper gel poured around the comb and allowed to polymerize to form
the sample wells of the gel. Samples, including a high molecular weight standard
(BioRad), were prepared (see above- preparation of radiolabled antigen) and loaded
onto the gel using a 100.0 µI, glass microsyringe and electrophoresed at 50.0 mA in
IX running buffer (0.025 M Tris-Base, 0.192 M glycine, and 0.1 % (w/v) SDS) for
4.0 hours. Following electrophoresis, the gel was placed in a staining solution (0.25
% Coomassie Brilliant Blue, 50.0 % methanol, and 10.0 % acetic acid) at RT for 1824 hours. The gel was fixed and destained in destaining solution (5.0 % methanol,
7.5 % glacial acetic acid in deionized water) at RT for 7-10 hours on a rocker table.
Following destaining, the gel was washed with deionized water, placed on a
Whatmann 3 MM paper cut to size, and covered on the exposed side with clear plastic
wrap. The gel was then dried on a slab drier (Model 443 Slab Dryer, BioRad) at
80.0 ° C with vacuum for 3.0 hours. The dried gel was then wrapped in clear plastic
wrap and exposed to Kodak X-OMAT AR film (Eastman Kodak Company,
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Rochester, NY) for 5-7 days. The film was then developed at RT by placement in
developer (Kodak) for 5.0 min, stop solution (5.0 % (v/v) glacial acetic acid in
deionized water) for 2.0 min and fixer (Kodak) for 5.0 min. The film was washed for
30.0 min with deionized water and then allowed to air dry at RT.

Hybridoma Cross Reactivity Assay

Determination ofcross reactivity ofhybridoma supematants with TPV
(Centers for Disease Control) was achieved through modifications of the procedure
outlined for IF screening (see above- Indirect Immunofluroescence and Digital
Imaging). Briefly, a triplicate set of OMK cell monolayers grown on cover slips
(Coming) were infected with the TPV isolate from the Centers for Disease Control
(CDC). The screening assay was then completed identically to the aforementioned IF
assay for determination ofhybridoma production ofanti-YLDV (ATCC) antibodies.

Determination ofViral Antigen as Either Early or Late Protein

Modifications to the IF screening assay were used to determine if the viral
antigen, to which any developed antibody produced was directed, is either an early or
late protein in the YLDV DNA synthesis pathway. OMK cell monolayers were
grown on cover slips as previously discussed (see Indirect Immunofluroescence).
The OMK cells were infected with YLDV in similar fashion and the virus particles
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allowed to absorb for 1.0 hour at RT on a rocker table. Following adsorption, the
supernatant was removed from the dish and 2.0 ml of maintenance medium
supplemented with 40.0 µg/ml of cytosine arabinoside (Ara-C) was added and the
dish incubated at 37.0° C with 5.0 % CO2 for 5-7 days; time course determined by
CPE displayed in dishes infected with YLDV maintained in maintenance medium
without addition of Ara-C- mock infected dishes. The supernatant was then removed
from the dish and the cells fixed per IF protocol. The cover slips were then taken
through the IF screening assay per protocol and viewed for positive staining results.

RESULTS

Development of Monoclonal Antibodies Directed Against Yaba-Like Disease Virus

Modifications to the technique developed by Kohler and Milstein (1975) were
used to develop hybridoma clones that produced monoclonal antibodies directed
against YLDV. Female BALB/c mice, 4-6 weeks old, were immunized against
YLDV, the immunized B-cells were then isolated and fused with mouse myeloma
cells via PEG. Over the course of two and one-half years, seven fusions were carried
out in our laboratory with varying results. The first fusion experiment resulted in 130
wells containing viable clones. All of these clones tested negative for anti-YLDV
antibody production through an IF screening assay (Table 1). The second and third
fusions both resulted in similar numbers of clones surviving to a point at which they
could be screened, all resulting with negative IF results.
Additional modifications to the procedure, as well as the materials used, were
made following the third fusion to possibly increase the number of viable clones that
were produced. One of the modifications was reducing the centrifugation speed from
1500 rpm to 1000 rpm used to pellet fused cells directly following dilution of the
PEG. This was done to possibly reduce the lysis of the freshly fused cells due to
forces exerted on the plasma membranes during centrifugation. The water used for
the preparation of all media for the hybridoma cells was changed from deionized
37
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water obtained from the departmental common facility, to sterile water for irrigation
(Baxter Healthcare Corporation, Deerfield, IL), to possibly eliminate any residual
endotoxin from the water source. Finally, the lot of FBS to be used for the media was
selected based on visual assessment of myeloma cell quality maintained in medium
supplemented with three separate lots, with the lot -resulting in the highest number of
viable cells per flask being selected.

Table 1
Summary of Number of Wells Screened per Fusion with Immunofluorescence Results
Fusion number

Wells Screeneda

Negative IFb

1

130

130

0

2

187

187

0

3

224

224

0

4

384

384

0

5

282

282

0

6

414

414

0

7

372

371

1

Positive IFc

a = 100.0 µI well supernatant was removed screened against YLDV infected and
mock infected OMK cells through IF; b = staining patterns similar on both YLDV
infected and uninfected cells; c = staining pattern resulting in high intensity
fluorescence on infected cells as compared to uninfected cells.
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These procedural modifications resulted in a greater number of viable cells,
but no increase in the number of clones. From all fusions only one hybridoma clone
H12, produced positive results through IF when supernatant was assayed against
YLDV-infected OMK cells and uninfected OMK cells.
The H12 clone developed in row H, column 12 of the third plate used in the
seventh fusion. H12 was recloned through limiting dilution and rescreened via IF.
Again, the supernatant from wells containing the recloned H12 cells produced
positive IF results against YLDV-infected cells and negative IF results against
uninfected cells. H12 was then cultivated and ultimately grown in 75 cm2 tissue
culture flasks for the production of large amounts of supernatant. H12 cells were
cryopreserved and three vials removed for testing of viability and antibody
production. All three vials removed from N2 produced viable cells and supernatant
that resulted in positive IF screening against YLDV-infected cells and negative IF
screening against uninfected cells.

Hybridoma Clone H12 Produces an IgGl Isotype Antibody

The technique developed by Oudin and Ouchterlony (reviewed in Nilsson,
1967) takes advantage of the cross-linking between an antibody contained in an
antiserum and a large antigen such as a protein or a polysaccharide. The cross
linking of these molecules often results in the formation of a precipitate. In this
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technique the antigen and antibody are allowed to diffuse towards each other through
agar, the precipitate will then be in the form of a visible line.
This technique was utilized to determine the isotype of the antibody secreted
by the H12 hybridoma clone. The supernatant from H12 cells grown in a 75 cm2
tissue culture flask was concentrated 25X in a B-15 clinical sample concentrator
(Millipore). The concentrated supernatant was then placed in a center well cut in a
solidified agar slab surrounded by six outer wells at equal distance from the center.
The six outer wells contained 5.0 µI of mouse monoclonal antibody isotyping reagent
(Sigma) each specific to a particular type of immunoglobulin heavy chain. The
resultant line of precipitation (Figure 1), demonstrated that the H12 monoclonal
antibody (mAb) is a type lgG1 antibody.

Indirect Immunofluorescence Microscopy with H12 Hybridoma Supernatant

Coons pioneered the use of fluorescent derivatives of antibodies to trace
antigen (Coons et al., 1941, 1942; Coons and Kaplan, 1950; Coons, 1961). It was
shown that antibodies could be coupled with �-anthracene or fluorescein isocyanate
with the retention of antigen-binding properties, and that these antibodies could be
used as sensitive probes to detect and localize antigen. Riggs et al. (1958) introduced
the more stable and continent fluorescein isothiocyanate (FITC), which is the most
popular fluorochrome used in fluorescent labeling experiments to date.
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Figure 1.

Ouchterlony Double Diffusion Analysis Demonstrating the Isotype of
the Antibody Secreted by Hybridoma Clone H l2. The wells contain
the following isotype reagents (clockwise from top): 1 ) anti-mouse
lgG 1; 2) anti-mouse IgG2a; 3) anti-mouse IgG2b; 4) anti-mouse IgG3;
5) anti-mouse lgM and 6) anti-mouse IgA. The center well contains
25X supernatant collected from 75 m2 tissue culture flask of
hybridoma clone H12. The reagents were added, the agar incubated at
37° C for 24 hours and all non-conjugated protein eluted with PBS for
24 hour at RT. The agar then was dried, stained in 0.1 % Coomassie
Brilliant Blue in deionized water solution and destained in 5.0 %
methanol, 7.0 % glacial acetic acid in deionized water solution.
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An anti-mouse IgG (whole molecule) FITC conjugate (anti-mouse IgG-FITC)
developed in goat (Sigma) was used to detect the binding pattern of the mAb secreted
by the hybridoma clone Hl2 on YLDV-infected OMK cells and uninfected OMK
cells by Immunofluorescence (Figure 2). At 7 days post-infection (dpi), Differential
Interference Microscopy (DIC) of YLDV-infected OMK cells demonstrated CPE
consistent with that observed for both TPV and YLDV in CV-1 cells (Knight et al.,
1989); a regressed monolayer with cytoplasmic granulation and vacuolization is
clearly evident (Fig. 2. A and D). IF of YLDV infected OMK cells, at 7 dpi, treated
with 25X H12 supernatant and anti-mouse IgG-FITC clearly demonstrate the areas of
viral replication within the cytoplasm of the infected cells termed ''viral factories"
(Fenner et al., 1989) (Fig. 2. B). An overlay of the DIC image and IF image for
YLDV-infected OMK cells treated with 25X H12 supernatant and anti-mouse IgG
FITC demonstrates the enlarged viral factories within these cells clearly labeled with
antibody, as evidenced by the areas of intense FITC staining coinciding with the areas
of surface membrane protrusion (Fig. 2. C). IF of YLDV-infected OMK cells, at 7
dpi, treated with anti-mouse IgG-FITC only, fail to show binding to the viral factories
(Fig. 2. E).
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Figure 2.

Indirect Irnmunofluorescence Microscopy Demonstrating the Selective
Binding of Hl2 to YLDV Infected Owl Monkey Kidney Cells. Cell
monolayers A, B, C, D, E, F were infected with YLDV at 50.0 pfu/cell
and ethanol fixed at 7 dpi. Monolayers A, B and C were treated with
25X Hl2 supernatant and anti-mouse IgG-FITC. Monolayers D, E and
F were treated with anti-mouse IgG-FITC only. Cell monolayers G, H
and I are uninfected cells, treated with 25X Hl2 supernatant and anti
mouse IgG-FITC. Images A, D and G are DIC micrographs. Images
B, E and H are IF micrographs. Images C, F and I are overlay
micrographs of A-B, D-E and G-H respectively. Bar = 50 µm.
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In fact, IF images of YLDV infected cells treated with anti-mouse lgG-FITC
only had staining patterns similar to that demonstrated for uninfected OMK cells
treated with 25X H12 supernatant and anti-mouse lgG-FITC (Fig. 2. D, E, F, G, H
and I). The results of the images obtained from IF demonstrate that the mAb secreted
by hybridoma clone H12 selectively binds to YLDV-infected OMK cells and not
uninfected OMK cells. Closer evaluation of theses images also reveals that the areas
of intense FITC staining are located only within the cytoplasm of YLDV-infected
cells, while there is no evidence of staining within the nucleus of these cells. These
combined results support the conclusion that the H12 mAb is directed against a
YLDV antigen.

H12 Antibody is Directed Against a Late YLDV Polypeptide

Infection of mammalian cells with various members of the poxvirus group
elicits the production of virus-induced proteins that differ in their time course of
synthesis in infected cells (Wilcox and Cohen, 1967; Moss, 1996). The proteins that
appear early during infection include enzymes responsible for nucleic acid
metabolism (Jungwirth and Joklik, 1965) and virion structural proteins (Holowczak
and Joklik, 1967a; Wilcox and Cohen, 1967; Sarov and Joklik, 1972; Fenger and
Rouhandeh, 1976; Esposito et al, 1977; Kilpatrick and Rouhandeh, 1981; Vafai and
Rouhandeh, 1982; reviewed in Moss, 1996). The late proteins which are those
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appearing after viral DNA synthesis are incorporated into newly synthesized virus as
structural components (Wilocx and Cohen, 1967).
Holowczak and Joklik (1967b) determined the temporal sequence of
synthesis of vaccinia virus structural proteins by employing an inhibitor of DNA
synthesis- cytosine arabinoside (Ara-C). We used this methodology to determine
whether the target antigen of the H12 mAb was an early or late protein ofYLDV. IF
microscopy of YLDV-infected OMK cells treated with Ara-C at 0.0 hours post
infection and YLDV-infected OMK cells not treated with Ara-C were ethanol fixed at
7 dpi and screened for antibody binding as previously discussed. The YLDV-infected
OMK cells treated with Ara-C (Fig. 3. A, B and C) failed to demonstrate any sign of
CPE even after 7dpi, as clearly evidenced in the DIC image of these monolayers (Fig.
3. A). In contrast, those cells that were infected with YLDV and not treated with
Ara-C (Fig. 3. D, E and F) demonstrated classic CPE, as shown in the DIC image of
these cells (Fig. 3. D). Fluorescent images ofYLDV-infected OMK cells treated with
Ara-C (Fig. 3. B) demonstrate no specific binding of the H12 mAb. While YLDV
infected OMK cells not treated with Ara-c (Fig. 3. E) show specific binding. The
results of these experiments show that the Hl2 mAb is directed against a late protein
synthesized following YLDV viral DNA synthesis. With that, this protein is most
likely a structural protein of the YLDV virion (Wilcox and Cohen, 1967).

46

A

B

C

D

E

F

Figure 3.

Indirect Immunofluorescence Microscopy Demonstrating H 12 Binding
Directed Against a Late YLDV Polypeptide. Cell monolayers A, B, C,
D, E, and F were infected with YLDV at 50.0 pfu/cell and ethanol
fixed at 7dpi. Images A, B and C represent cell monolayers that were
treated with 40.0 µg/ml Ara-C at 0 hours post infection. Images D, E,
and F represent monolayers that were not treated with Ara-C. A and D
are DIC images, B and E are fluorescent images, and C and F are
overlay images of A-B and D-E respectively. Bar = 50 µm.
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H12 Antibody Demonstrates Cross Reactivity with TPV Through Indirect
Immunofluorescence Microscopy

YLDV and TPV have previously been shown to share similar biological
properties (Downie et al., 197 1 ; Espana, 1966; Hull, 1968; McNulty et al., 1968), as
well as being indistinguishable in serological experiments in an attempt to recognize
different antigenic properties between YLDV and TPV (Downie and Espana, 1972).
IF microscopy was used to demonstrate the binding of the H12 mAb to TPV
infected OMK cells. TPV-infected OMK cell monolayers were ethanol fixed at 7 dpi,
treated with 25X Hl2 supernatant and anti-mouse IgG-FITC. The results from these
experiments are summarized in Figure 4. TPV-infected OMK cells treated with 25X
H12 supernatant and anti-mouse IgG-FITC (Fig. 4. A, Band C) demonstrate identical
binding patterns to that were seen with YLDV-infected OMK cells treated identically
(Fig. 2. A, B and C). Also, TPV-infected OMK cells treated with anti-mouse IgG
FITC only (Fig. 4. D, E and F) show no specific binding, which is identical to the
results from YLDV-infected cells treated similarly (Fig. 2. D, E, and F). These
results demonstrate that the Hl2 mAb cross reacts with YLDV and TPV with
resultant binding patterns that are indistinguishable. These results support those that
have been previously reported for antigenic similarity between YLDV and TPV in
complement-fixation tests, neutralization tests, precipitation tests and active immunity
experiments (Downie and Espana, 1972).
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Figure 4.

Indirect Immunofluorescence Microscopy Demonstrating H 12 Cross
Reactivity with TPV. Cell monolayers A, B, C, D, E, and F were
infected with TPV and ethanol fixed at 7 dpi. Images A, B and C
represent cell monolayers that were treated 25X H 12 supernatant and
anit-mouse IgG-FITC. Images D, E, and F represent monolayers that
were treated with ani-mouse lgG-FITC only. A and D are DIC
images, B and E are fluorescent images, and C and F are overlay
images of A-B and D-E respectively. Bar = 50 µm.
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Immunoprecipitation of Viral Antigen with H12 Supernatant Demonstrates Two
Polypeptide Chains Precipitated

Radiolabeling of the antigen provides a sensitive basis for its detection, and
has the major attraction that non-labeled proteins such as antibodies may be added
without detection in the final readout. This approach was pioneered by Schwartz and
Nathenson (1971) and has been widely adopted to study hundreds of different
antigens.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SOS-PAGE)
was used to resolve the viral antigen to which the H12 mAb is directed. Samples of
soluble protein were prepared from YLDV-infected OMK cells and non-infected
cells. The samples were then treated with either 25X H12 supernatant or a dilution of
an anti-mouse lgG antibody (anti-mouse lgG) and allowed to precipitate over night.
Following a series of centrifugation and wash cycles the samples, along with a high
molecular weight standard, were then loaded on an 11.5 % polyacrylamide gel for
resolution. The results from an SOS-PAGE of immunoprecipitates are summarized in
Figure 5. The YLDV-infected cell sample treated with H12 supernatant (Fig. 5. lane
1) shows the presence of two distinct bands- a 40.7 kDa protein and a 26.9 kDa
protein; that are not present in either the sample of YLDV-infected cells treated with
the anti-mouse IgG (Fig. 5. lane 3) or the uninfected cells treated with H12
supernatant (Fig. 5. lane 4). Samples of the YLDV-infected cells and un-infected
cells were centrifuged prior to the addition of H12 supernatant (Fig. 5. lanes 2 and 5
respectively) to remove all non-specific protein bands seen in previous experiments.
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Figure 5.
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Autoradiogram of Immunoprecipitates with H12 Demonstrating
Precipitation of Two Polypeptide Chains. Cell monolayers infected
with YLDV at 50.0 pfu/cell were radiolabeled with 35S-methionine for
4.0 hours at 7 dpi (lanes 1, 2 and 3). Mock-infected cell monolayers
were labeled with 35S-methionine for 4.0 hours following 7 days in
maintenance medium. Cells were harvested and plasma membranes
lysed with 1.0 % NP-40 with 1.0:1.0 (v/v) Immunoprecipitation buffer
added following treatment with detergent and removal of nuclei via
centrifugation. An aliquot of 50.0 µl of YLDV-infected cells (lane 1)
and mock-infected cells (lane 4) were treated with 50.0 µl of 25.0X
H12 supernatant, 50.0 µl of YLDV-infected cell (lane 2) and mock
infected cells (lane 5) were centrifuged at 12,000 x g for 20.0 min
prior to addition 50.0 µ1 25.0X H12 supernatant, and YLDV-infected
cells (lane 3) and mock-infected cells (lane 6) were treated with 50.0
µl of 1.0:20.0 dilution of a.-mlgG in PBS; all samples were incubated
at 37.0° C for 24 hours. An anti-mouse lgG in a 1.0:100.0 (v/v)
dilution in PBS was added following 24 hours to all samples and
incubated for an additional 4.0 hours at 37.0° C. Each sample was
then centrifuged at 12,000 x g for 20.0 min and the pellet washed with
0.85 % (w/v) NaCl in deionized water 3X. The samples were then
loaded on an 11.5 % polyacrylamide gel as described by Laemelli
(1970). Standard molecular weights are indicated on the left in
kilodaltons.

DISCUSSION
The results of the experiments performed for the completion of this project
demonstrate the development of a single hybridoma clone H12, which secretes an
anti-YLDV IgG1 isotype antibody that cross reacts with TPV. Difficulties
experienced in the development of monoclonal antibodies against the YLDV virus
may be due to the immunosuppressive properties of the virus itself. Throughout the
course of immunization we did not observe any signs of viral replication in the
immunized mice, so this suppression does not seem to be an active process in this
model. With that, the immunosuppressive characteristics of viral antigens to evade
detection of the host immune system seem to play the greatest role when considering
the number of anti-YLDV hybridomas that were produced throughout seven separate
fusions. The YLDV virion proved to be an extremely difficult particle to raise
monoclonal antibodies against.
H12 has proven to be a stable cell line surv1vmg cryopreservation and
conserving its antibody secreting properties. Ouchterlony double diffusion assay has
shown the antibody secreted by the H12 hybridoma to be an IgGl isotype antibody.
This antibody has been shown to specifically bind to areas consistent with those
described for viral replication in YLDV and TPV infected OMK cells and not
uninfected cells through Indirect Immunofluorescence microscopy. Ara-C inhibition
of viral DNA synthesis was used to show that the viral antigen is a late protein in the
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temporal sequence of YLDV replication. Also, an immunoprecipitation experiment
has shown two polypeptides- a 40 kDa polypeptide and a 26.9 kDa polypeptide, to be
resolved when YLDV infected cell plasma membranes and cytoplasmic extracts were
precipitated with the H12 mAb.

Although the results of the immunoprecipitation

experiment presented seem clear, these results- could not be repeated through
numerous attempts.

Modifications such as isotopes at various concentrations,

separate immunoprecipitation buffers, various time intervals of starvation and
labeling of the infected cells, differing concentrations and volumes of supernatant
added to the sample, etc, were all attempted over the last year with out repeating the
results presented with in this manuscript.

It is not uncommon for monoclonal

antibodies to fail to form precipitates in vitro, it has been previously demonstrated
that seemingly minor modifications to antigen or antibody occurring for known for
unknown reasons may result in complete abolishment of antibody binding
(Nussenweig, et al., 1982). A number of alternate experiments may resolve the viral
antigen of the H12 mAb. A western blot ofYLDV infected OMK cell and uninfected
cell protein treated with the H12 mAb and the appropriate controls may lead to the
confirmation of the target antigen. Another possibility would be to again attempt an
immunoprecipitation experiment with purified H12 mAb via a protein A column.
Also, to try to maximize the amount of antibody recovered, a buffer that contains high
pH and high salt concentration may be a suitable choice given that mouse IgG1
antibodies have been shown to bind strongly in this type pf buffer solution (Goding,
1996).

The purified antibody could then be titrated in order form optimum
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precipitates and avoid the prozone phenomenon (failure to form precipitates due to
antigen or antibody excess).
There are many potential uses for this antibody as a reagent in the basic
research of both YLDV and TPV.

The H12 mAb may possibly facilitate the

elucidation of the molecular mechanisms of the - virus-host interactions.

It also

demonstrates the potential for being used as a clinical reagent in the diagnosis of
YLDV and TPV. Samples taken from those primates where infection from either of
these two pathogens is suspected could be properly prepared and stained wit the H12
mAb to detect the presence of either YLDV or TPV.

Appendix A
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